Heart Pump Patent Battle: Who Really Wins in Court?

A major medical device company just won a court case that could shape how heart pumps get made in the future. A jury decided that Abiomed’s Impella heart pumps don’t break Maquet’s patent rules. Even more surprising? The jury said Maquet’s patent itself wasn’t even valid. That’s a double win for Abiomed, which makes these life-supporting pumps. But why does this matter beyond the courtroom? The case started back in 2017 when Maquet sued Abiomed, arguing that their rival heart pumps copied a key design idea. The fight dragged on for years, with courts flip-flopping until the appeals court brought it back to life. Now, with the jury’s decision, Abiomed can keep selling its pumps without legal trouble—at least for now.This isn’t just about patents. It’s about money too. Johnson & Johnson bought Abiomed in 2022 for a massive $16. 6 billion, betting big on heart pumps as a future cash cow. Last year alone, Impella pumps brought in $1. 75 billion in sales worldwide. That’s a lot of funding for a company to protect. But here’s the catch: these pumps haven’t been trouble-free. The FDA has recalled some models in recent years, raising questions about safety even as the legal battle wraps up. The bigger picture? Heart pumps like Impella are lifesavers for people with severe heart failure. They temporarily take over the heart’s job, keeping patients alive until they can recover or get a transplant. But with patents and lawsuits flying, companies might spend more time in court than improving these devices. The ongoing second lawsuit shows this fight isn’t over yet.